Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
Items 201–362 of 362
Rubinstein, M. P., Kadima, A. N., Salem, M. L., Nguyen, C. L., Gillanders, W. E., & Cole, D. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4928 · Cited by 93 · cited 3×
“Combined use with TAA-pulsed DC vaccine [149]”
BackgroundLenzi, R., Edwards, R. P., June, C. H., Seiden, M. V., Garcia, M. E., Rosenblum, M. G., & Freedman, R. S. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-66 · Cited by 93 · cited 1×
“Of note, there were earlier trials with direct intraperitoneal administration of recombinant IL-12 in patients with peritoneal carcinomatosis but satisfactory effects were not achieved [160].”
IL-15 Regulates Both Quantitative and Qualitative Features of the Memory CD8 T Cell Pool
Sandau, M. M., Kohlmeier, J. E., Woodland, D. L., & Jameson, S. C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0803355 · Cited by 91 · cited 2×
“Advantages of IL-15 in tumor immunotherapy result from its unique ability to activate important mechanisms of antitumor immunity, including development and activity of both NK cells [10–12] and CD8 T cells [13–16], and promoting a persistent immune response through its action on memory T cells [16–20].”
BackgroundLocal targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment
Fransen, M. F., Arens, R., & Melief, C. J. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27755 · Cited by 89 · cited 1×
“As shown and stressed in many recent reports, strong immunosuppressive mechanisms operate in the microenvironment in advanced tumor and IL-12 is expected, on the one hand, to overcome this phenomenon and, on the other hand, to induce specific antitumor mechanisms [158, 159].”
BackgroundPelletier, M., Ratthé, C., & Girard, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03668-2 · Cited by 89
Interleukin-15 Activates Proinflammatory and Antimicrobial Functions in Polymorphonuclear Cells
Musso, T., Calosso, L., Zucca, M., Millesimo, M., Puliti, M., Bulfone-Paus, S., Merlino, C., Savoia, D., Cavallo, R., Ponzi, A. N., et al. (1998) · Infection and Immunity · doi:10.1128/iai.66.6.2640-2647.1998 · Cited by 89 · cited 1×
“It stimulates NF-kB activation and production of IL-8 in neutrophils and enhances their phagocytic and antimicrobial activity [68,81,82].”
BackgroundDifferential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms
Gaggero, A., Azzarone, B., Andrei, C., Mishal, Z., Meazza, R., Zappia, E., Rubartelli, A., & Ferrini, S. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199904)29:04<1265::aid-immu1265>3.0.co;2-v · Cited by 89 · cited 1×
“and is regulated at the level of translation, intracellular trafficking, and secretion [34–36].”
BackgroundIdentification of IFN-γ-Producing Cells in IL-12/IL-18-Treated Mice
Otani, T., Nakamura, S., Toki, M., Motoda, R., Kurimoto, M., & Orita, K. (1999) · Cellular Immunology · doi:10.1006/cimm.1999.1589 · Cited by 87 · cited 1×
“1): increasing production of IFN-γ, which is the most potent mediator of IL-12 actions, from NK and T cells [26]; stimulation of growth and cytotoxicity of activated NK cells, CD8+ and CD4+ T cells [27], shifting differentiation of CD4+ Th0 cells toward the Th1 phenotype [28]; enhancement of antibody-dependent cellula…”
BackgroundIL‐12‐Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivoa
Zitvogel, L., Couderc, B. C., Mayordomo, J. I., Robbins, P. D., Lotze, M. T., & Storkus, W. J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb52678.x · Cited by 87
Trentin, L., Cerutti, A., Zambello, R., Sancretta, R., Tassinari, C., Facco, M., Adami, F., Rodeghiero, F., Agostini, C., & Semenzato, G. (1996) · Blood · doi:10.1182/blood.v87.8.3327.bloodjournal8783327 · Cited by 87
Yao, L., Pike, S. E., Setsuda, J., Parekh, J. R., Gupta, G. D., Raffeld, M. A., Jaffe, E. S., & Tosato, G. (2000) · Blood · doi:10.1182/blood.v96.5.1900 · Cited by 86
Eng, V. M., Car, B. D., Schnyder, B., Lorenz, M., Lugli, S., Aguet, M., Anderson, T. D., Ryffel, B., & Quesniaux, V. F. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1893 · Cited by 86
Dai, Z., Arakelov, A., Wagener, M. E., et al. (1999) · PubMed · Cited by 84
Waldmann, T. A. (2002) · Arthritis Research · doi:10.1186/ar584 · Cited by 83
Hoontrakoon, R., Chu, H. W., Gardai, S. J., Wenzel, S. E., McDonald, P. P., Fadok, V. A., Henson, P. M., & Bratton, D. L. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.4.4517 · Cited by 83 · cited 2×
“Interleukin 15 has been found to up-regulate anti-apoptotic proteins BCL-2, BCL-xL, MCL-1 [88–91], downregulate pro-apoptotic proteins BAX, BID, BIM, NOXA, PUMA [91– 93], stimulate activity of NF-kB [84], and to inhibit that of caspase3 and -8 [83,92].”
BackgroundAvice, M.-N., Demeure, C. E., Delespesse, G., Rubio, M., Armant, M. A., & Sarfati, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3408 · Cited by 83 · cited 1×
“The antitumor effects of IL-15 may also result from its ability to induce production of cytokines, including TNF-a [107] and IL-12 [108].”
BackgroundBiologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).
Sarmiento, U. M., Riley, J. W., Knaack, P. A., Lipman, J. M., Becker, J. M., Gately, M. K., Chizzonite, R., & Anderson, T. D. (1994) · PubMed · Cited by 82
Expression of Interleukin-15 in Mouse and Human Atherosclerotic Lesions
Wuttge, D. M., Eriksson, P. O., Sirsjö, A., Hansson, G. K., & Stemme, S. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61712-9 · Cited by 82 · cited 1×
“IL-15 also seems to contribute to the induction of coronary heart disease [156,157].”
BackgroundAlphavirus vectors for cancer therapy
Quetglas, J. I., Ruiz-Guillen, M., Aranda, A., Casales, E., Bezunartea, J., & Smerdou, C. (2010) · Virus Research · doi:10.1016/j.virusres.2010.07.027 · Cited by 82
IL‐15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3
Imamichi, H., Sereti, I., & Lane, H. C. (2008) · European Journal of Immunology · doi:10.1002/eji.200737607 · Cited by 82 · cited 2×
“regulatory FoxP3 Tab cells [159,160] in a manner similar to IL-7 [22] but less potent than IL-2 [8,22].”
BackgroundHamid, O., Solomon, J. C., Scotland, R., Garcia, M., Sian, S., Ye, W., Groshen, S. L., & Weber, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1450 · Cited by 82 · cited 3×
“1 Intratumoral Melanoma [149] 1 3 in a monotherapy with rituximab, given at the same dose (375 mg/m2) and similar schedule, has been found to range between 47 and 73 % [155].”
Pulendran, B., Dillon, S. M., Joseph, C., Curiel, T. J., Banchereau, J., & Mohamadzadeh, M. (2003) · European Journal of Immunology · doi:10.1002/eji.200324567 · Cited by 81 · cited 1×
“CD40, CD80/86 molecules [33], and making them potent inducers of CD4 and CD8 T cell responses [77].”
BackgroundMechanism of synergistic effect of chemotherapy and immunotherapy of cancer
Ramakrishnan, R., & Gabrilovich, D. I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0930-1 · Cited by 81 · cited 1×
“Nevertheless, several chemotherapeutics, for example cyclophosphamide, paclitaxel, 5-fluorouracil, 5-aza-2′deoxycitidine, mitomycin, doxorubicin, and mitoxantrone, have been shown to demonstrate improved antitumor activity in mice when combined with immunotherapy ([65], for review, see [78, 79]).”
BackgroundVagliani, M., Rodolfo, M., Cavallo, F., Parenza, M., Melani, C. C., Parmiani, G., Forni, G., & Colombo, M. P. (1996) · PubMed · Cited by 80
Rossi, A., Pericle, F., Rashleigh, S., Janiec, J., & Djeu, J. (1994) · Blood · doi:10.1182/blood.v83.5.1323.1323 · Cited by 80
Alatrash, G., Hutson, T. E., Molto, L., Richmond, A., Nemec, C., Mekhail, T., Elson, P., Tannenbaum, C., Olencki, T., Finke, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.045 · Cited by 79
Suppressive Influences in the Immune Response to Cancer
Bronte, V., & Mocellin, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181837276 · Cited by 78 · cited 1×
“blocking the immune response against TAAs [109], the development of immunologic tolerance towards TAAs [110], and the”
BackgroundCytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
Haicheur, N., Escudier, B., Dorval, T., Negrier, S., De Mulder, P. H. M., Dupuy, J. M., Novick, D., Guillot, T., Wolf, S., Pouillart, P., et al. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2000.01112.x · Cited by 78 · cited 4×
“These effects were associated with IFN-γ production, and further on, two more downstream mediators were described: IFN-γ-inducible protein 10 (IP-10, CXCL10) and monokine induced by IFN-γ (MIG, CXCL9) [41].”
BackgroundMethodInfluentialDecot, V., Voillard, L., Latger‐Cannard, V., Aïssi-Rothé, L., Perrier, P., Stoltz, J., & Bensoussan, D. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.02.006 · Cited by 78 · cited 4×
“Advantages of IL-15 in tumor immunotherapy result from its unique ability to activate important mechanisms of antitumor immunity, including development and activity of both NK cells [10–12] and CD8 T cells [13–16], and promoting a persistent immune response through its action on memory T cells [16–20].”
BackgroundInfluentialNeely, G. G., Robbins, S. M., Amankwah, E. K., Epelman, S., Wong, H., Spurrell, J. C. L., Jandu, K. K., Zhu, W., Fogg, D. K., Brown, C. B., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5011 · Cited by 78 · cited 1×
“agonists of Toll-like receptors (TLRs) including LPS, doublestranded RNA, and unmethylated CpG oligonucleotides [31–33],”
BackgroundInterleukin-12: Clinical usage and molecular markers of cancer susceptibility
Yuzhalin, A. E., & Kutikhin, A. G. (2012) · Growth Factors · doi:10.3109/08977194.2012.678843 · Cited by 78 · cited 1×
“IL-12-based immunotherapy could be especially efficacious in cancer patients with inherited defects of IL-12 production [187] or with downregulated expression of IL-12 [188].”
BackgroundThe interleukin‐15/interleukin‐15 receptor system as a model for juxtacrine and reverse signaling
Bulfone‐Paus, S., Bulanova, E., Budagian, V., & Paus, R. (2006) · BioEssays · doi:10.1002/bies.20380 · Cited by 77 · cited 2×
“includes intracrine, autocrine, paracrine, and endocrine signaling ([40,41] and reviewed in [26]).”
BackgroundTatsumi, T., Takehara, T., Kanto, T., Miyagi, T., Kuzushita, N., Sugimoto, Y., Jinushi, M., Kasahara, A., Sasaki, Y., Hori, M., et al. (2001) · PubMed · Cited by 77
Chen, Y., Emtage, P. C. R., Zhu, Q., Foley, R., Muller, W. J., Hitt, M., Gauldie, J., & Wan, Y. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301396 · Cited by 76 · cited 1×
“IL-12 gene has also been successfully used in vaccines consisting of tumor antigens [98], tumor cells [99, 100], or dendritic cells [101–103].”
MethodMoga, E., Álvarez, E., Cantó, E., Vidal, S., Rodríguez-Sánchez, J. L., Sierra, J., & Briones, J. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.012 · Cited by 75 · cited 2×
“Combined use with antitumor monoclonal antibodies [143]”
BackgroundDi Carlo, E., Comes, A., Basso, S., De Ambrosis, A., Meazza, R., Musiani, P., Moelling, K., Albini, A., & Ferrini, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3111 · Cited by 74 · cited 3×
“cytokines delayed growth of wild-type tumor cells injected contralaterally, and induced complete rejection of those cells when they were admixed with transfected tumor cells before injection [150].”
BackgroundMethodInfluentialKuniyasu, H., Ohmori, H., Sasaki, T., Sasahira, T., Yoshida, K., Kitadai, Y., & Fidler, I. J. (2003) · PubMed · Cited by 74
Pouw, N. M. C., Treffers-Westerlaken, E., Kraan, J., Wittink, F. R. A., ten Hagen, T., Verweij, J., & Debets, R. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0818-0 · Cited by 74 · cited 4×
“The capacity of IL-15 used alone [141] or in combination with IL-21 [128] or chemotherapy [133] to further enhance efficacy of adoptive immunotherapy seems to be particularly promising.”
BackgroundMethodInfluentialHansson, L., Abdalla, A. O., Moshfegh, A., Choudhury, A., Rabbani, H., Nilsson, B. R., Österborg, A., & Mellstedt, H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1603 · Cited by 73 · cited 1×
“Multiple myeloma [138]”
Avice, M.-N., Demeure, C. E., Delespesse, G., et al. (1998) · PubMed · Cited by 73
Wennerberg, E., Sarhan, D., Carlsten, M., Kaminskyy, V. O., D’Arcy, P., Zhivotovsky, B., Childs, R. W., & Lundqvist, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28163 · Cited by 72 · cited 1×
“1 3 activity of T cytotoxic cells and NK cells [81].”
BackgroundGene Therapy of Cancer with Interleukin-12
Mazzolini, G. D., Prìeto, J., & Melero, I. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454261 · Cited by 72 · cited 1×
“Autologous dendritic cells transfected with adenovirus encoding IL-12 gene Intratumoral Gastrointestinal carcinomas [146]”
BackgroundDuvic, M. A., Sherman, M. L., Wood, G. S., Kuzel, T. M., Olsen, E. A., Foss, F. M., Laliberte, R. J., Ryan, J. L., Zonno, K., & Rook, A. H. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.06.038 · Cited by 72
Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity
Palmer, K., Hitt, M., Emtage, P. C. R., Gyorffy, S., & Gauldie, J. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301386 · Cited by 71 · cited 1×
“IP-10 in adenoviral vector; intratumoral injection PyMT-induced mammary adenocarcinoma, MCA 207 sarcoma IL-12 in adenoviral vector; intratumoral injection [111]”
MethodLuedke, E., Jaime-Ramirez, A. C., Bhave, N., Roda, J., Choudhary, M. M., Kumar, B., Teknos, T. N., & Carson, W. E. (2012) · Surgery · doi:10.1016/j.surg.2012.05.035 · Cited by 71
Lasek, W., Feleszko, W., Gołąb, J., Stokłosa, T., Marczak, M., Dabrowska-Iwanicka, A. P., Malejczyk, M., & Jakóbisiak, M. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050408 · Cited by 71 · cited 2×
“TNF-α Mice B16F10 melanoma, Lewis lung carcinoma, L1 sarcoma [45]”
BackgroundSelf-citationOttonello, L. C., Frumento, G., Arduino, N., Bertolotto, M. B., Dapino, P., Mancini, M., & Dallegri, F. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.125 · Cited by 71 · cited 1×
“Interleukin 15 has been found to up-regulate anti-apoptotic proteins BCL-2, BCL-xL, MCL-1 [88–91], downregulate pro-apoptotic proteins BAX, BID, BIM, NOXA, PUMA [91– 93], stimulate activity of NF-kB [84], and to inhibit that of caspase3 and -8 [83,92].”
BackgroundKhawam, K., Giron‐Michel, J., Gu, Y., Perier, A., Giuliani, M., Caignard, A., Devocelle, A., Ferrini, S., Fabbi, M., Charpentier, B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3198 · Cited by 70
Habibi, M., Kmieciak, M., Graham, L., Morales, J. K., Bear, H. D., & Manjili, M. H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0024-3 · Cited by 68 · cited 3×
“other interleukins, including IL-7 [130] and IL-12 [120].”
BackgroundMethodZhu, S., Lee, D. A., & Li, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902371 · Cited by 68
Mendiratta, S. K., Quezada, A., Matar, M. M., Wang, J., Hebel, H. L., Long, S., Nordstrom, J. L., & Pericle, F. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300891 · Cited by 68 · cited 1×
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundAntitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review).
Gołąb, J., & Zagożdżon, R. (1999) · International Journal of Molecular Medicine · doi:10.3892/ijmm.3.5.537 · Cited by 67
Self-citationThe Regulation and Biological Activity of Interleukin 12
Lee, S. M., Suen, Y., Qian, J., Knoppel, E., & Cairo, M. S. (1998) · Leukemia & Lymphoma · doi:10.3109/10428199809050903 · Cited by 67
Rodolfo, M., Zilocchi, C., Melani, C. C., Cappetti, B., Arioli, I., Parmiani, G., & Colombo, M. P. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.12.5536 · Cited by 65 · cited 1×
“IL-12 gene has also been successfully used in vaccines consisting of tumor antigens [98], tumor cells [99, 100], or dendritic cells [101–103].”
MethodNishimura, H., Fujimoto, A., Tamura, N., Yajima, T., Wajjwalku, W., & Yoshikai, Y. (2005) · The FASEB Journal · doi:10.1096/fj.04-2633com · Cited by 65 · cited 1×
“short signal peptide plays a role in the negative feedback control of IL-15 expression and/or activity either inhibiting its transcription [38] or competing for binding to IL-15Ra [39].”
BackgroundHodge, D. L., Yang, J., Buschman, M. D., Schaughency, P., Dang, H., Bere, W., Yang, Y., Savan, R., Subleski, J. J., Yin, X., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3735 · Cited by 65 · cited 1×
“Interleukin 15 has been found to up-regulate anti-apoptotic proteins BCL-2, BCL-xL, MCL-1 [88–91], downregulate pro-apoptotic proteins BAX, BID, BIM, NOXA, PUMA [91– 93], stimulate activity of NF-kB [84], and to inhibit that of caspase3 and -8 [83,92].”
BackgroundBasile, L. A., Ellefson, D., Gluzman-Poltorak, Z., Junes-Gill, K., Mar, V., Mendonca, S., Miller, J. D., Tom, J., Trinh, A., & Gallaher, T. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030434 · Cited by 64 · cited 1×
“Combining radiotherapy and IL-12 may also have additional advantage as IL-12 could not only potentiate antitumor effects of radiotherapy [71] but could diminish acute radiotherapy injury, according to observation in non-human primates [83].”
BackgroundCollapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas
Kerkar, S. P., Leonardi, A. J., van Panhuys, N., Zhang, L., Yu, Z., Crompton, J. G., Pan, J. H., Palmer, D. C., Morgan, R. A., Rosenberg, S. A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.58 · Cited by 64 · cited 3×
“These are potent antiangiogenic effects via induction of antiangiogenic cytokine and chemokine production [32], remodeling of the peritumoral extracellular matrix and tumor stroma [33], reprogramming of myeloid-derived suppressor cells [34], and changes in processing and increasing expression of MHC class I molecules…”
BackgroundInfluentialAnwer, K., Kelly, F. J., Chu, C., Fewell, J. G., Lewis, D. H., & Alvarez, R. D. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.081 · Cited by 63 · cited 1×
“Seventeen percent of the patients had complete response, 33 % partial response, 42 % stable disease, and 8 % of the patients progressed [162].”
BackgroundQuetglas, J. I., Dubrot, J., Bezunartea, J., Sanmamed, M. F., Hervás‐Stubbs, S., Smerdou, C., & Melero, I. (2012) · Molecular Therapy · doi:10.1038/mt.2012.56 · Cited by 62 · cited 1×
“Agonistic anti-CD137 agonistic antibody; systemic administration B16-OvA melanoma, TC-1 lung carcinoma IL-12 in SFv vector [114]”
BackgroundMitsuhashi, M., Liu, J., Cao, S., Shi, X., & Ma, X. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1203641 · Cited by 62 · cited 1×
“Suppression of IL-12 production is mediated by such cytokines as type I IFNs [19], IL-10, and TGF-β [20] as well as by prostaglandin e2 (PGe2) that is produced by various cancers [21].”
BackgroundBouchard, A., Ratthé, C., & Girard, D. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1103585 · Cited by 62 · cited 2×
“Interleukin 15 has been found to up-regulate anti-apoptotic proteins BCL-2, BCL-xL, MCL-1 [88–91], downregulate pro-apoptotic proteins BAX, BID, BIM, NOXA, PUMA [91– 93], stimulate activity of NF-kB [84], and to inhibit that of caspase3 and -8 [83,92].”
BackgroundYoshimoto, T., Nagai, N., Ohkusu, K., Ueda, H., Okamura, H., & Nakanishi, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.3.1483 · Cited by 61 · cited 1×
“1): increasing production of IFN-γ, which is the most potent mediator of IL-12 actions, from NK and T cells [26]; stimulation of growth and cytotoxicity of activated NK cells, CD8+ and CD4+ T cells [27], shifting differentiation of CD4+ Th0 cells toward the Th1 phenotype [28]; enhancement of antibody-dependent cellula…”
BackgroundCTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
Phan, G. Q., Weber, J. S., & Sondak, V. K. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0104-y · Cited by 60 · cited 1×
“immune response can induce serious autoimmune reactions including colitis, dermatitis, and hypophysitis [146].”
BackgroundInterleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases.
Gately, M. K., Gubler, U., Brunda, M. J., Nadeau, R. R., Anderson, T. D., Lipman, J. M., & Sarmiento, U. M. (1994) · PubMed · Cited by 60
Wadler, S., Levy, D. E., Frederickson, H., Falkson, C. I., Wang, Y., Weller, E. A., Burk, R. D., Ho, G. Y. F., & Kadish, A. S. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.022 · Cited by 59 · cited 1×
“Antitumor effects of IL-12 were evaluated in various treatment schedules: intravenous [121–123] versus subcutaneous [124, 125] or even intraperitoneal application [126], daily and five consecutive injections every 3 weeks [121, 122, 127], or at 1 [124, 125, 128], 2 [123], or 3 [129] Table 2 Tumor gene therapy with int…”
MethodAnsell, S. M., Geyer, S. M., Maurer, M. J., Kurtin, P. J., Micallef, I. N., Stella, P. J., Etzell, P. S., Novak, A. J., Erlichman, C., & Witzig, T. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1245 · Cited by 59 · cited 1×
“Non-Hodgkin’s lymphoma [135]”
IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy
Helms, M. W., Prescher, J. A., Cao, Y., Schaffert, S. A., & Contag, C. H. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0860-y · Cited by 58
Little, R. F., Aleman, K. O., Kumar, P. P., Wyvill, K. M., Pluda, J. M., Read-Connole, E., Wang, V., Pittaluga, S., Catanzaro, A. T., Steinberg, S. M., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097568 · Cited by 58
Fogler, W. E., Völker, K., Watanabe, M., Wigginton, J. M., Roessler, P. G., Brunda, M. J., Ortaldo, J. R., & Wiltrout, R. H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6014 · Cited by 58
de Jong, J. L., Farner, N. L., Widmer, M. B., Giri, J. G., & Sondel, P. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.4.1339 · Cited by 57
Redmond, W. L., Gough, M. J., & Weinberg, A. D. (2009) · European Journal of Immunology · doi:10.1002/eji.200939348 · Cited by 57 · cited 1×
“induction of anergy of tumor-reactive lymphocytes [111].”
Bergamaschi, C., Jalah, R., Kulkarni, V., Rosati, M., Zhang, G.-M., Alicea, C., Zolotukhin, A. S., Felber, B. K., & Pavlakis, G. N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900693 · Cited by 56
Mignot, G., Ullrich, E., Bonmort, M., Menard, C., Apétoh, L., Taı̈eb, J., Bosisio, D., Sozzani, S., Ferrantini, M., Schmitz, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6477 · Cited by 55 · cited 2×
“homeostasis of IFN-producing killer dendritic cells, stimulating their proliferation, enhancing their cytotoxic activity towards tumor cells, and according them the ability to induce antitumor response in vivo [106].”
BackgroundTaams, L. S., van Eden, W., & Wauben, M. H. M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199905)29:05<1543::aid-immu1543>3.0.co;2-r · Cited by 55
GENOMIC STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN INTERLEUKIN 15 GENE (IL–15)
Krause, H., Jandrig, B., Wernicke, C., Bulfone‐Paus, S., Pohl, T., & Diamantstein, T. (1996) · Cytokine · doi:10.1006/cyto.1996.0089 · Cited by 55
Management of indolent lymphoma: Where are we now and where are we going
Lunning, M. A., & Vose, J. M. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.09.004 · Cited by 55 · cited 1×
“1 3 in a monotherapy with rituximab, given at the same dose (375 mg/m(2)) and similar schedule, has been found to range between 47 and 73 % [155].”
BackgroundGeneration of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer
Perro, M., Tsang, J. Y., Xue, S., Escors, D., Cesco-Gaspere, M., Pospori, C., Gao, L., Hart, D. P., Collins, M. K., Stauss, H. J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.4 · Cited by 53 · cited 1×
“15 combined with IL-21 has been used for the improved lentiviral transfer of T-cell receptor (TCR) genes into human non-proliferating T cells [139], and to achieve enhanced antitumor effects of TCRtransduced tumor-specific T cells [128].”
MethodLeite‐de‐Moraes, M., Lisbonne, M., Arnould, A., Machavoine, F., Herbelin, A., Dy, M., & Schneider, E. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200207)32:7<1839::aid-immu1839>3.0.co;2-y · Cited by 53
Yoshimoto, T., Nagai, N., Ohkusu, K., et al. (1998) · PubMed · Cited by 53
Huarte, E., Fisher, J. L., Turk, M. J., Mellinger, D., Foster, C., Wolf, B., Meehan, K. R., Fadul, C. E., & Ernstoff, M. S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.05.003 · Cited by 52 · cited 4×
“Both effector and central memory CD8 T cells are stimulated by IL-15 [18–20,98].”
BackgroundMethodInfluentialSteel, J. C., Ramlogan‐Steel, C. A., Yu, P., Sakai, Y., Forni, G., Waldmann, T. A., & Morris, J. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1301 · Cited by 52
Wigginton, J. M., Park, J., Gruys, M. E., Young, H. A., Jorcyk, C. L., Back, T. C., Brunda, M. J., Strieter, R. M., Ward, J. M., Green, J. E., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1156 · Cited by 52 · cited 1×
“IL-2 Mice Mammary carcinoma [66]”
Homma, S., Sagawa, Y., Ito, M., Ohno, T., & Toda, G. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03029.x · Cited by 51 · cited 1×
“There is a concern, however, that such a treatment can induce systemic autoimmune response [178].”
BackgroundTriozzi, P. L., Allen, K. O., Carlisle, R. R., Craig, M. C., LoBuglio, A. F., & Conry, R. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2283 · Cited by 51 · cited 1×
“1 Intratumoral Melanoma [149]”
Cao, S., Troutt, A. B., & Rustum, Y. M. (1998) · PubMed · Cited by 51
Memarian, A., Nourizadeh, M., Masoumi, F., Tabrizi, M. H., Emami, A. H., Alimoghaddam, K., Hadjati, J., Mirahmadian, M., & Jeddi‐Tehrani, M. (2012) · Tumor Biology · doi:10.1007/s13277-012-0578-x · Cited by 51 · cited 1×
“Direct cell–cell contact has also been described as a mechanism of decreasing IL-12 production, for instance by tumor-derived CD4+CD25+ T regulatory (Treg) lymphocytes via CTLA-4-mediated signaling [23] or by CD200– CD200R interactions [24].”
BackgroundFewell, J. G., Matar, M. M., Rice, J. S., Brunhoeber, E., Slobodkin, G., Pence, C., Worker, M., Lewis, D. H., & Anwer, K. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1356 · Cited by 50 · cited 1×
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundDrela, N., Jalili, A., Kamiński, R., Kozar, K., Jak�bisiak, M., Lasek, W., Basak, G. W., Świtaj, T., Jakubowska, A. B., Wysocki, P. J., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0449-9 · Cited by 50 · cited 4×
“Antitumor effects of IL-12 were evaluated in various treatment schedules: intravenous [121–123] versus subcutaneous [124, 125] or even intraperitoneal application [126], daily and five consecutive injections every 3 weeks [121, 122, 127], or at 1 [124, 125, 128], 2 [123], or 3 [129] All-trans-retinoic acid in liposome…”
BackgroundInfluentialSelf-citationKozar, K., Kamiński, R., Świtaj, T., Ołdak, T., Machaj, E. K., Wysocki, P. J., Mackiewicz, A. A., Lasek, W., Jakóbisiak, M., & Gołąb, J. (2003) · PubMed · Cited by 50
Self-citationAfter Initial Setback, IL-12 Regaining Popularity
Jenks, S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.9.576 · Cited by 49 · cited 3×
“This resulted in the immediate halting of all trials with IL-12 by the US FDA [118]. explanation for the different tolerability in phase I versus phase II trial was a change in the dosing schedule.”
BackgroundInfluentialFogler, W. E., Völker, K., Watanabe, M., et al. (1998) · PubMed · Cited by 48
Song, K.-L., Chang, Y., & Prud’homme, G. J. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301274 · Cited by 47
Murine interleukin-12 prevents the development of cancer cachexia in a murine model
Mori, K., Fujimoto-Ouchi, K., Ishikawa, T., Sekiguchi, F., Ishitsuka, H., & Tanaka, Y. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960917)67:6<849::aid-ijc15>3.0.co;2-x · Cited by 47 · cited 1×
“Although application of IL-12 in mice was found to prevent the development of cancer cachexia [84], it was accompanied by hematologic toxicities including anemia, lymphopenia, neutropenia, and also muscle and hepatic toxicities [85].”
BackgroundTriozzi, P. L., Strong, T. V., Bucy, R. P., Allen, K. O., Carlisle, R. R., Moore, S. E., LoBuglio, A. F., & Conry, R. M. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.91 · Cited by 45 · cited 2×
“In fact, response rates in NHLs a Peptides: gp100209–217 (210M), MART-126–35 (27L), tyrosinase368–376 (370D), adjuvant: Montanide ISA 51 b Peptides: gp100209–217 (210M), tyrosinase368–376 (370D), adjuvant: Montanide ISA 51 c Peptide: Melan-A27–35 Combined treatment Trastuzumab i.v. Breast, pancreas, cervical cancer [1…”
Comes, A., Carlo, E. D., Musiani, P., Rosso, O., Meazza, R., Chiodoni, C., Colombo, M. P., & Ferrini, S. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200207)32:7<1914::aid-immu1914>3.0.co;2-p · Cited by 45
Lin, C., Chuang, T.-F., Liao, K., Huang, Y.-J., Pai, C.-C. S., & Chu, R. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.07.016 · Cited by 44 · cited 1×
“been demonstrated to restore NK cell anti-tumor activity inhibited by transforming growth factor b (TGF-b) [115].”
BackgroundCharoensit, P., Kawakami, S., Higuchi, Y., Yamashita, F., & Hashida, M. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.12 · Cited by 43
Dendritic/Tumor Fusion Cells as Cancer Vaccines
Avigan, D., Rosenblatt, J. M., & Kufe, D. W. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.003 · Cited by 42 · cited 1×
“Immunotherapy with dendritic cells/tumor cells (DC/TC) fusion vaccine represents a promising approach in clinical oncology since it optimizes the presentation of a broad array of tumor antigens along both MHC class I and II pathways [170].”
BackgroundWang, J. M., Cheng, J., Li, G. Y., Wu, X. Y., Thayer, P., Greer, P., Smith, A. M., High, K. P., Moorman, J. P., & Yao, Z. Q. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.03.003 · Cited by 41
Xia, J., Liu, W., Hu, B., Tian, Z., & Yang, Y. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.011 · Cited by 40 · cited 1×
“regulatory FoxP3 Tab cells [159,160] in a manner similar to IL-7 [22] but less potent than IL-2 [8,22].”
BackgroundŚwitaj, T., Jalili, A., Jakubowska, A. B., Drela, N., Stoksik, M., Nowis, D., Basak, G. W., Gołąb, J., Wysocki, P. J., Mackiewicz, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0022 · Cited by 40 · cited 1×
“CpG ODN; intratumoral injection B78-H1 melanoma vaccine (IL-12-transduced tumor cells) [116]”
BackgroundSelf-citationDirect stimulation of macrophages by IL-12 and IL-18 — a bridge too far?
Gołąb, J., Zagożdżon, R., Stokłosa, T., Kamiński, R., Kozar, K., & Jakóbisiak, M. (2000) · Immunology Letters · doi:10.1016/s0165-2478(00)00178-4 · Cited by 38 · cited 1×
“Classical examples of such cytokines are TNF-α [45, 46], IL-2 [47, 48], IL-15 [49, 50], IL-18 [50, 51], or GM-CSF [52].”
BackgroundSelf-citationPappo, I., Tahara, H., Robbins, P. D., Gately, M. K., Wolf, S. F., Barnea, A., & Lotze, M. T. (1995) · Journal of Surgical Research · doi:10.1006/jsre.1995.1034 · Cited by 38
Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo
Hazama, S., Noma, T., Wang, F., Iizuka, N., Ogura, Y., Yoshimura, K., Inoguchi, E., Hakozaki, M., Hirose, K., Suzuki, T., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690538 · Cited by 37 · cited 1×
“prostate cancer cells engineered to secrete IL-15 have also been completely rejected following injection into normal [151,152] or nude mice [153].”
BackgroundGökkuşu, C., Aydın, M., Özkök, E., Tülübaş, F., Elitok, A., Pamukçu, B., & Umman, B. (2009) · Cytokine · doi:10.1016/j.cyto.2009.09.004 · Cited by 37 · cited 1×
“IL-15 also seems to contribute to the induction of coronary heart disease [156,157].”
BackgroundDirect inhibition of human acute myeloid leukemia cell growth by IL-12
Ferretti, E., Carlo, E. D., Cocco, C., Ribatti, D., Sorrentino, C., Ognio, E., Montagna, D., Pistoia, V., & Airoldi, I. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.08.002 · Cited by 37 · cited 1×
“Although potent antitumor effects of IL-12 are very well established, this cytokine is considered to be incapable of directly inhibiting the cancer growth, although exceptions can occur [25].”
BackgroundExpression of interleukin 15 in primary adult acute lymphoblastic leukemia
Wu, S., Fischer, L., Gökbuget, N., Schwartz, S., Burmeister, T., Notter, M., Hoelzer, D. F., Fuchs, H., Blau, I. W., Hofmann, W. K., et al. (2009) · Cancer · doi:10.1002/cncr.24729 · Cited by 36
Cao, L., Zeng, Q., Xu, C., Shi, S., Zhang, Z., & Sun, X. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300602j · Cited by 36 · cited 1×
“Paclitaxel B16 melanoma IL-12 in adenoviral vector; intratumoral injection [59]”
BackgroundRowley, J. W., Monie, A., Hung, C., & Wu, T. ‐. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8237 · Cited by 36 · cited 1×
“includes intracrine, autocrine, paracrine, and endocrine signaling ([40,41] and reviewed in [26]).”
BackgroundApproval of Provenge Seen As First Step for Cancer Treatment Vaccines
Brower, V. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq295 · Cited by 36 · cited 1×
“dritic cells pulsed with prostatic acid phosphatase-GM-CSF fusion protein, evokes new hope [148].”
BackgroundCody, J. J., Scaturro, P., Cantor, A. B., Gillespie, G. Y., Parker, J. N., & Markert, J. M. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/628697 · Cited by 35
Teicher, B. A., Ara, G., Buxton, D., Leonard, J., & Schaub, R. G. (1997) · PubMed · Cited by 34
D’Agostino, P., Milano, S., Arcoleo, F., Bella, G. D., Rosa, M. L., Ferlazzo, V., Caruso, R., Chifari, N., Vitale, G., Mansueto, S., et al. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01522.x · Cited by 34
Teicher, B. A., Ara, G., Menon, K., & Schaub, R. G. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960103)65:1<80::aid-ijc14>3.0.co;2-m · Cited by 34 · cited 1×
“This cytokine has been successfully applied in dozens of experimental models in mice involving both solid tumors and hematologic malignancies including poorly immunogenic tumors [56–60].”
BackgroundLasek, W., Golab, J., Maśliński, W., Świtaj, T., Bałkowiec, E. Z., Stokłosa, T., Giermasz, A., Malejczyk, M., & Jakóbisiak, M. (1999) · PubMed · Cited by 33
Self-citationInterleukin-12 Receptor β2: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies
Pistoia, V., Cocco, C., & Airoldi, I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3579 · Cited by 33 · cited 1×
“, IL-12R-β1 in B cells [12]) or inducible (IL-12R-β2 [12]) manner in a variety of immune cells, including NK cells, T, and B lymphocytes.”
BackgroundCD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity
Chen, X., Du, Y., & Huang, Z. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.09.002 · Cited by 33 · cited 1×
“Direct cell–cell contact has also been described as a mechanism of decreasing IL-12 production, for instance by tumor-derived CD4+CD25+ T regulatory (Treg) lymphocytes via CTLA-4-mediated signaling [23] or by CD200– CD200R interactions [24].”
BackgroundSaikh, K. U., Kissner, T. L., Nystrom, S., Ruthel, G. T., & Ulrich, R. G. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00320-07 · Cited by 33 · cited 2×
“dendritic cells, participates in their activation, proliferation and differentiation [33,75,76], promoting expression of MHC class II,”
BackgroundGołąb, I., Stokłosa, T., Zagożdżon, R., Kaca, A., Giermasz, A., Pojda, Z., Machaj, E. K., Dąbrowska, A., Feleszko, W., Lasek, W., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008266321552 · Cited by 33 · cited 2×
“It is worth mentioning that erythropoietin was found to prevent the development of IL-12-induced anemia and thrombocythemia in mice [54] and G-CSF prevented the suppression of bone marrow myelopoiesis [53].”
BackgroundSelf-citationTan, C., Reddy, V., Dannull, J., Ding, E., Nair, S. K., Tyler, D. S., Pruitt, S. K., & Lee, W. T. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-148 · Cited by 31
Zhu, X., Sun, H., Xu, H., Kong, L., Chai, Z., Lu, L., Zhang, J., Gao, D., Wang, W., Zhang, W., et al. (2013) · Angiogenesis · doi:10.1007/s10456-013-9357-6 · Cited by 30 · cited 1×
“1 3 angiogenesis has been underscored by a recent observation that antiangiogenic therapy with vascular endothelial growth factor receptor (veGFR) inhibitors, sunitinib and sorafenib, promoted metastasis of hepatocellular carcinoma model by suppressing host-derived IL-12B (IL12-p40) [42].”
BackgroundInterleukin-15 Expression Is Associated with Malignant Potential in Colon Cancer Cells
Kuniyasu, H., Oue, N., Nakae, D., Tsutsumi, M., Denda, A., Tsujiuchi, T., Yokozaki, H., & Yasui, W. (2001) · Pathobiology · doi:10.1159/000048761 · Cited by 30
Eisenbeis, C. F., Lesinski, G. B., Anghelina, M. I., Parihar, R., Valentino, D., Liu, J., Nadella, P. C., Sundaram, P. K., Young, D. C., Sznol, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1691 · Cited by 30 · cited 1×
“Melanoma, renal cancer, and other cancers [142, 143]”
IL‐15 is critical for the maintenance and innate functions of self‐specific CD8+ T cells
Itsumi, M., Yoshikai, Y., & Yamada, H. (2009) · European Journal of Immunology · doi:10.1002/eji.200839106 · Cited by 29 · cited 1×
“T lymphocytes [154] and participate in the development of autoimmune diseases such as rheumatoid arthritis, multiple”
BackgroundLesinski, G. B., Badgwell, B., Zimmerer, J., Crespin, T., Hu, Y., Abood, G., & Carson, W. E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7368 · Cited by 29
Li, S., Xia, X., Mellieon, F. M., Liu, J., & Steele, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.022 · Cited by 29 · cited 1×
“These effects were associated with IFN-γ production, and further on, two more downstream mediators were described: IFN-γ-inducible protein 10 (IP-10, CXCL10) and monokine induced by IFN-γ (MIG, CXCL9) [41].”
BackgroundIL-15 and IL-15Ralpha in CD4+T cell immunity.
Belle, T. V., & Grooten, J. (2005) · PubMed · Cited by 28
No Requirement of Trans Presentations of IL-15 for Human CD8 T Cell Proliferation
Ota, N., Takase, M., Uchiyama, H., Olsen, S. K., & Kanagawa, O. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901834 · Cited by 28 · cited 1×
“Thus, IL-15 seems to function under normal circumstances as a cell-bound cytokine and is trans-presented to responding cells together with co-stimulatory signals ([46] and reviewed in [55]), although the dominance of trans-presentation of IL-15 to CD8 T cells has recently been called into question [56].”
BackgroundKimura, K. B., Nishimura, H., Matsuzaki, T., Yokokura, T., Nimura, Y., & Yasunobu, Y. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050604 · Cited by 28 · cited 4×
“from potentiated activation by these cytokines of both NK and CD8 T cells [120].”
BackgroundMethodInfluentialInterleukin‐15 enhances proliferation and chemokine secretion of human follicular dendritic cells
Gil, M., Park, S. H., Chung, Y., & Park, C. S. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03252.x · Cited by 27 · cited 2×
“dendritic cells, participates in their activation, proliferation and differentiation [33,75,76], promoting expression of MHC class II,”
BackgroundBasak, G. W., Zapała, Ł., Wysocki, P. J., Mackiewicz, A., Jakóbisiak, M., & Lasek, W. (2008) · Oncology Reports · doi:10.3892/or.19.5.1173 · Cited by 27 · cited 5×
“Combined use with cytokine gene-modified tumor cell vaccine [121]”
BackgroundMethodInfluentialSelf-citationImmunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency
Kimura, K. B., Nishimura, H., Hirose, K., Matsuguchi, T., Nimura, Y., & Yoshikai, Y. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199905)29:05<1532::aid-immu1532>3.0.co;2-z · Cited by 27 · cited 1×
“prostate cancer cells engineered to secrete IL-15 have also been completely rejected following injection into normal [151,152] or nude mice [153].”
BackgroundIrradiation and IL-15 promote loss of CD8 T-cell tolerance in response to lymphopenia
Oelert, T., Papatriantafyllou, M., Pougialis, G., Hämmerling, G. J., Arnold, B., & Schüler, T. (2010) · Blood · doi:10.1182/blood-2009-06-227298 · Cited by 26 · cited 1×
“immunosuppressive action of Tregs [23], and can potentially reverse unresponsiveness of CD8 T cells to tumor cells abrogating tolerance to TAAs [112–114], which was not observed with IL-2 treatment [112].”
BackgroundHuang, C., Ramakrishnan, R., Trkulja, M., Ren, X., & Gabrilovich, D. I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1198-9 · Cited by 25 · cited 1×
“IL-12 gene has also been successfully used in vaccines consisting of tumor antigens [98], tumor cells [99, 100], or dendritic cells [101–103].”
MethodSharif‐Askari, E., Fawaz, L. M., Tran, P., Ahmad, A., & Menézes, J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1724 · Cited by 25
Sipuleucel-T for the Treatment of Advanced Prostate Cancer
Frohlich, M. W. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.004 · Cited by 24
Suzuki, S., Umezu, Y., Saijo, Y., Satoh, G., Abe, Y., Satoh, K., & Nukiwa, T. (1998) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.185.223 · Cited by 24 · cited 1×
“These are potent antiangiogenic effects via induction of antiangiogenic cytokine and chemokine production [32], remodeling of the peritumoral extracellular matrix and tumor stroma [33], reprogramming of myeloid-derived suppressor cells [34], and changes in processing and increasing expression of MHC class I molecules…”
BackgroundQuetglas, J. I., Rodríguez-Madoz, J. R., Bezunartea, J., Ruiz-Guillen, M., Casales, E., Medina‐Echeverz, J., Prìeto, J., Berraondo, P., Hervás‐Stubbs, S., & Smerdou, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201791 · Cited by 24 · cited 1×
“The IL-12 gene has been introduced in various viral [88–90] and non-viral [91–93] vectors, directly into growing tumors [92, 94–96] or in IL-12-engineered fibroblasts injected at the site of an established tumor [97].”
BackgroundGołąb, J., Zagożdżon, R., Kamiński, R., Kozar, K., Gryska, K., Iżycki, D., Mackiewicz, A. A., Stokłosa, T., Giermasz, A., Lasek, W., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402076 · Cited by 24 · cited 1×
“5-fluorouracil Mice L1210 leukemia [62]”
Self-citationKing, J. P., Thomas, S., Corsi, F., Gao, L., Dina, R. E., Gillmore, R., Pigott, K., Kaisary, A. V., Stauss, H. J., & Waxman, J. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1821 · Cited by 23 · cited 1×
“immunosuppressive action of Tregs [23], and can potentially reverse unresponsiveness of CD8 T cells to tumor cells abrogating tolerance to TAAs [112–114], which was not observed with IL-2 treatment [112].”
BackgroundIL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215950 · Cited by 23
Xia, X., Li, X., Feng, G., Zheng, C., Liang, H., & Zhou, G. (2013) · Acta Radiologica · doi:10.1177/0284185113480072 · Cited by 21
Zagożdżon, R., Stokłosa, T., Gołąb, J., Giermasz, A., Dabrowska-Iwanicka, A. P., Lasek, W., & Jakóbisiak, M. (1997) · PubMed · Cited by 21
Self-citationIdentification and characterization of polyclonal αβ-T cells with dendritic cell properties
Kuka, M., Munitić, I., & Ashwell, J. D. (2012) · Nature Communications · doi:10.1038/ncomms2223 · Cited by 20
Yin, J., Dai, A., Laddy, D. J., Yan, J., Arango, T., Khan, A. S., Lewis, M. G., Andersen, H., Kutzler, M. A., Draghia, R., et al. (2009) · Virology · doi:10.1016/j.virol.2009.07.017 · Cited by 20 · cited 1×
“immune response against influenza antigens in a non-human primate model [162].”
BackgroundBasile, L. A., Gallaher, T. K., Shibata, D. K., Miller, J. D., & Douer, D. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-26 · Cited by 19 · cited 1×
“Interesting observations have also been made regarding the actions, either positive or negative, of IL-12 on hematopoiesis [53–55], which can be of importance in cancer patients as well.”
BackgroundFelzmann, T., Buchberger, M., Lehner, M., Printz, D., Kircheis, R., Wagner, E., Gadner, H., & Holter, W. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00526-2 · Cited by 18
Zagożdżon, R., Gołąb, J., Mucha, K., Foroncewicz, B., & Jakóbisiak, M. (1999) · International Journal of Molecular Medicine · doi:10.3892/ijmm.4.6.645 · Cited by 17 · cited 1×
“Paclitaxel Mice MmB16 melanoma [61]”
Self-citationWilczyńska, U., Kucharska, A., Szary, J., & Szala, S. (2001) · Acta Biochimica Polonica · doi:10.18388/abp.2001_3868 · Cited by 17 · cited 1×
“injection B16F10 melanoma IL-12-encoding plasmid; intratumoral injection [107]”
Linette, G. P., Hamid, O., Whitman, E. D., Nemunaitis, J. J., Chesney, J. A., Agarwala, S. S., Starodub, A., Barrett, J. A., Andrew, M., Martell, L. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3022 · Cited by 17
Radiation therapy and breast reconstruction
Moulds, J., & Berg, C. D. (1998) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1998)6:2<71::aid-roi2>3.0.co;2-e · Cited by 14 · cited 2×
“Radiotherapy Mice Lewis lung carcinoma [71]”
BackgroundGołąb, J., Zagożdżon, R., Stokłosa, T., Lasek, W., Jakóbisiak, M., Pojda, Z., & Machaj, E. K. (1998) · Blood · doi:10.1182/blood.v91.11.4387 · Cited by 14
Self-citationGołąb, J., Zagożdżon, R., Kozar, K., Kamiński, R., Giermasz, A., Stokłosa, T., Lasek, W., & Jakóbisiak, M. (2000) · Oncology Reports · doi:10.3892/or.7.1.177 · Cited by 13
Self-citationPeripheral Helper Lymphocytes Produce Interleukin 12 in Cancer Patients
Michelin, M. A., Abdalla, D. R., Aleixo, A. A. R., & Murta, E. F. C. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s11292 · Cited by 12
Tsukamoto, K., Huang, Y. C., Dorsey, W. C., Carns, B., & Sharma, V. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03240.x · Cited by 11 · cited 2×
“includes intracrine, autocrine, paracrine, and endocrine signaling ([40,41] and reviewed in [26]).”
BackgroundSynergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model
Zapała, Ł., Wolny, R., Wachowska, M., Jakóbisiak, M., & Lasek, W. (2012) · Oncology Reports · doi:10.3892/or.2012.2193 · Cited by 9 · cited 1×
“vaccine (dendritic cells pulsed with tumor cell lysate) Mice B78-H1 melanoma Hepatocellular carcinoma BNL [73] [74]”
BackgroundSelf-citationInterleukin-12 Gene Therapy Vaccines: Directing the Immune System against Minimal Residual Leukemia
Dunussi‐Joannopoulos, K., & Leonard, J. P. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109060339 · Cited by 9 · cited 1×
“IL-12 gene has also been successfully used in vaccines consisting of tumor antigens [98], tumor cells [99, 100], or dendritic cells [101–103].”
Methodb, J. G. L. A., Stokłosa, T., on, R. L. A. Z. Z. D. Z., Kaca, A., Kulchitska, L. A., Feleszko, W., Kawiak, J., Hoser, G., owacka, E. G. L., browska, A. D. A., et al. (1998) · Tumor Biology · doi:10.1159/000029978 · Cited by 7 · cited 2×
“Classical examples of such cytokines are TNF-α [45, 46], IL-2 [47, 48], IL-15 [49, 50], IL-18 [50, 51], or GM-CSF [52].”
BackgroundSelf-citationDabrowska-Iwanicka, A. P., Giermasz, A., Gołąb, J., & Jakóbisiak, M. (2001) · PubMed · Cited by 5
TIM3 suppresses antitumour DCs
Alderton, G. K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3349 · Cited by 4 · cited 1×
“Another suppressive molecule is T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), which can inhibit the production of IL-12 by dendritic cells [15] within a tumor environment (highlighted in [22]).”
BackgroundFelzmann, T., Buchroithner, J., Marosi, C., Nowosielski, M., Oberndorfer, S., Ruckser, R., Rössler, K., Azizi, A. A., von Campe, G., & Bordihn, K. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4658 · Cited by 2
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.